Καναδάς - Αγγλικά - Health Canada

astrazeneca canada inc - influenza virus type a (h1n1); influenza virus type a (h3n2); influenza virus type b - spray - 10000000ffu; 10000000ffu; 10000000ffu - influenza virus type a (h1n1) 10000000ffu; influenza virus type a (h3n2) 10000000ffu; influenza virus type b 10000000ffu - vaccines

Καναδάς - Αγγλικά - Health Canada

astrazeneca canada inc - influenza virus type a (h1n1); influenza virus type a (h3n2); influenza virus type b (victoria); influenza virus type b (yamagata) - spray - 32000000ffu; 32000000ffu; 32000000ffu; 32000000ffu - influenza virus type a (h1n1) 32000000ffu; influenza virus type a (h3n2) 32000000ffu; influenza virus type b (victoria) 32000000ffu; influenza virus type b (yamagata) 32000000ffu - vaccines

Μαλαισία - Αγγλικά - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - influenza split virus, inactivated -

Ισραήλ - Αγγλικά - Ministry of Health

sanofi israel ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - suspension for injection - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen - vaxigrip tetra is indicated for the prevention of influenza disease caused by the two influenza a virus subtypes and the two influenza b virus types contained in the vaccine for:- active immunisation of adults, including pregnant women, and children from 6 months of age and older- passive protection of infant(s) from birth to less than 6 months of age following vaccination of pregnant women.the use of vaxigrip tetra should be based on official recommendations.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/california/7/2009 (h1n1) - like strain 9ug (a/california/7/2009 nymc x-179a); influenza virus a/texas/50/2012 (h3n2) like strain 9ug (a/texas/50/2012 nymc x-223a); influenza virus b/massachusetts/2/2012 like strain 9ug (wild type) - suspension for injection - 9 mcg - active: influenza virus a/california/7/2009 (h1n1) - like strain 9ug (a/california/7/2009 nymc x-179a) influenza virus a/texas/50/2012 (h3n2) like strain 9ug (a/texas/50/2012 nymc x-223a) influenza virus b/massachusetts/2/2012 like strain 9ug (wild type) excipient: dibasic sodium phosphate dihydrate hydrochloric acid monobasic potassium phosphate potassium chloride sodium chloride sodium hydroxide water for injection - intanza 9mcg is indicated for prophylaxis of influenza in adults from 18 to 59 years of age. the use of intanza 9mcg in new zealand should be based on the ministry of health recommendations for influenza vaccination as published in the current new zealand immunisation handbook.

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - a/california/7/2009 (h1n1)pdm09 - derived strain used nymc x-179a a/victoria/361/2011 (h3n2) - derived strain used ivr-165 b/massachusetts/2/2012 - suspension for injection - 7.5 mcg ea %v/v

Μάλτα - Αγγλικά - Medicines Authority

abbott biologicals b.v. - influenza vaccine (split virion, inactivated) 15 µg - suspension for injection in pre-filled syringe

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/singapore/gp1908/2015, ivr-180); influenza virus a/switzerland/8060/2017 (h3n2) like strain 15ug (a/brisbane/1/2018, nymc x-311); influenza virus b/colorado/06/2017 - like strain 15ug (b/maryland/15/2016, nymc bx-69a (victoria lineage)); influenza virus b/phuket/3073/2013 - like strain 15ug (b/phuket/3073/2013, wild type (yamagata lineage)) - suspension for injection - 0.5 ml - active: influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/singapore/gp1908/2015, ivr-180) influenza virus a/switzerland/8060/2017 (h3n2) like strain 15ug (a/brisbane/1/2018, nymc x-311) influenza virus b/colorado/06/2017 - like strain 15ug (b/maryland/15/2016, nymc bx-69a (victoria lineage)) influenza virus b/phuket/3073/2013 - like strain 15ug (b/phuket/3073/2013, wild type (yamagata lineage)) excipient: d-alpha-tocopheryl acid succinate dibasic sodium phosphate dodecahydrate magnesium chloride hexahydrate monobasic potassium phosphate octoxinol polysorbate 80 potassium chloride sodium chloride water for injection - fluarix tetra is a quadrivalent vaccine indicated for active immunisation of adults and children from 6 months of age for the prevention of influenza disease caused by the influenza virus types a and b contained in the vaccine. the use of fluarix tetra should be based on official recommendations.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - influenza virus a (h1n1) haemagglutinin 15ug (a/victoria/4897/2022 (h1n1)pdm09-like strain (a/victoria/4897/2022, ivr-238)); influenza virus a (h3n2) haemagglutinin 15ug (a/thailand/8/2022 (h3n2)-like strain (a/california/122/2022, san-022)); influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021 - like strain (b/michigan/01/2021, wild type)); influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013 - like strain (b/phuket/3073/2013, wild type)) - suspension for injection - 60 mcg - active: influenza virus a (h1n1) haemagglutinin 15ug (a/victoria/4897/2022 (h1n1)pdm09-like strain (a/victoria/4897/2022, ivr-238)) influenza virus a (h3n2) haemagglutinin 15ug (a/thailand/8/2022 (h3n2)-like strain (a/california/122/2022, san-022)) influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021 - like strain (b/michigan/01/2021, wild type)) influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013 - like strain (b/phuket/3073/2013, wild type)) excipient: octoxinol 9 phosphate buffered saline - fluquadri is indicated for active immunisation of influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. fluquadri is indicated for use in adults and children 6 months and older.

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 7.5ug (a/michigan/45/2015, x-275); influenza virus a/singapore/infimh-16-0019/2016 (h3n2) - like strain 7.5ug (a/singapore/infimh-16-0019/2016, nib-104); influenza virus b/brisbane/60/2008 - like strain 7.5ug (b/brisbane/60/2008 (victoria lineage)); influenza virus b/phuket/3073/2013 - like strain 7.5ug (b/phuket/3073/2013 (yamagata lineage)) - suspension for injection - 30 mcg - active: influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 7.5ug (a/michigan/45/2015, x-275) influenza virus a/singapore/infimh-16-0019/2016 (h3n2) - like strain 7.5ug (a/singapore/infimh-16-0019/2016, nib-104) influenza virus b/brisbane/60/2008 - like strain 7.5ug (b/brisbane/60/2008 (victoria lineage)) influenza virus b/phuket/3073/2013 - like strain 7.5ug (b/phuket/3073/2013 (yamagata lineage)) excipient: octoxinol 9 phosphate buffered saline - fluquadri junior is indicated for active immunisation of influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. fluquadri junior is indicated for use in children aged 6 months to 35 months inclusive.